Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma

Solomon A. Graf(University of Washington Medical Center), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sandra Kanan(University of Washington Medical Center), Qian Wu(Cancer Research Center), Karolyn Morris(University of Washington Medical Center), Thomas R. Chauncey(City Of Hope National Medical Center), Heather Rasmussen(University of Washington Medical Center), Fatemeh Behnia(Active Medicine (United Kingdom)), Jenna Voutsinas(Fred Hutch Cancer Center), Elizabeth F. Krakow(Fred Hutch Cancer Center), Ryan D. Cassaday(University of Washington), Stephen D. Smith(Seattle Cancer Care Alliance), Lorinda Soma(University of Washington), Ryan C. Lynch(Seattle Cancer Care Alliance)
Clinical Lymphoma Myeloma & Leukemia
December 3, 2020
10.1016/j.clml.2020.11.023
Cited by 13

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
|Blood|2003|407
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
|JAMA|2011|320